UNSPSC 51111652: Piritrexim

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C17H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, MK2A783ZUT chemically known as 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine but generally known as piritrexim, which bears US NIH Compound Identifier 54369. European Medicines Agency schedules Piritrexim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09921MIG.

UNSPSC 51111652 Piritrexim is a Commodity code that covers pharmaceutical active ingredients and their sourcing, though state and local procurement activity under this code centers on direct-to-manufacturer prescription fulfillment programs rather than the ingredient itself. The Texas Health and Human Services Commission has used this code designation in a Request for Information issued in April 2026 to solicit vendor capabilities for implementing direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers. State health and human services agencies appear to be the primary issuing bodies pursuing this procurement, focusing on establishing alternative channels outside traditional pharmacy benefit managers and group purchasing organizations to improve prescription fulfillment efficiency and manage drug costs. Vendors responding must demonstrate experience with direct contracting for self-insured employers and government health plans, ability to negotiate net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements.

The code shows recent activity in Texas, with the Texas Health and Human Services Commission posting RFI No. HHS0017013 with a response deadline of April 3, 2026. This was an exploratory information-gathering solicitation rather than a formal competitive procurement, designed to inform the state's future acquisition strategy before issuing a formal RFP. The RFI sought vendor input on direct-contracting strategies, volume fulfillment capabilities, and participation in multi-jurisdictional government purchasing organizations. No award value, budget range, set-asides, or binding timelines were specified at the RFI stage, as the state was conducting foundational market research on available solutions and vendor capabilities to support pharmacy benefit objectives.